Find a Clinical Trial

Is a clinical trial right for you? Search our database to find studies for which you may be eligible.

Browse All Clinical Trials

Viewed View Trial

NRG-BR008: A Phase III Randomized Trial Of Radiotherapy Optimization For Low-Risk HER2-POSITIVE Breast Cancer HERO

Study Type: Treatment

Phase: III

NCTID: NCT05705401

Principal Investigator: Shane Stecklein

Viewed View Trial

Phase I Trial Of Alpelisib Plus Sacituzumab Govitecan In Patients With Metastatic Or Locally Recurrent HER2-Negative Breast Cancer

Study Type: Treatment

Phase: I

NCTID: NCT05143229

Principal Investigator: Priyanka Sharma

Viewed View Trial

Phase IIA Trial of Acolbifene 20 mg vs Low Dose Tamoxifen 5 mg in Pre-menopausal Women at High Risk for Development of Breast Cancer

Study Type: Prevention

Phase: II

NCTID: NCT05941520

Principal Investigator: Carol Fabian

Viewed View Trial

Randomized Phase II Trial of Fulvestrant or Exemestane With or Without Ribociclib After Progression on Anti-Estrogen Therapy Plus Cyclin-Dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer MAINTAIN

Study Type: Treatment

Phase: II

NCTID: NCT02632045

Principal Investigator: Anne O'Dea

Viewed View Trial

A Phase I/II Trial Evaluating the Safety and Efficacy of Eribulin in Combination with Copanlisib in Patients with Metastatic Triple Negative Breast Cancer

Study Type: Treatment

Phase: I/II

NCTID: NCT04345913

Principal Investigator: Shane Stecklein

Viewed View Trial

A Phase II Randomized Trial of Olaparib NSC-747856 Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

Study Type: Treatment

Phase: II

NCTID: NCT03598257

Principal Investigator: Priyanka Sharma

Viewed View Trial

Selective Use of Observation After Lumpectomy and Sentinel Lymph Node Biopsy in Her-2 Positive Patients with Pathologic Complete Response to Neoadjuvant Chemotherapy

Study Type: Treatment

Phase: I/II

NCTID: NCT03460067

Principal Investigator: Shane Stecklein

Viewed View Trial

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring STMDDM versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer

Study Type: Health Services

Phase: N/A

NCTID: NCT03723928

Principal Investigator: Gary Doolittle

Viewed View Trial

Phase III Randomized Trial of Hypofractionated Post mastectomy Radiation With Breast Reconstruction

Study Type: Supportive Care

Phase: III

NCTID: NCT03414970

Principal Investigator: Jamie Wagner

Viewed View Trial

A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant AZD9833, a Next-Generation, Oral Selective Estrogen Receptor Degrader Versus Standard Endocrine Therapy Aromatase Inhibitor or Tamoxifen as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

Study Type: Treatment

Phase: III

NCTID: NCT05952557

Principal Investigator: Qamar Khan